A 225 patient Phase 2b clinical trial commenced in July 2024 in multiple centres in Denmark and in Hong Kong. The trial is focused on patients with more severe OA, which aligns with patients who reported significant reduction in pain in the Phase 2a trial. As of January 2025, the trial is running on schedule […]
Read More1. Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Alan Reynolds, Nicholas Larkins, Peter Alexandersen, Helene Rovsing, Robert Moots and Philip G. Conaghan. The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial. Osteoarthritis and Cartilage. 2024 Jul;32(7):952-962. doi: 10.1016/j.joca.2024.02.948. 2. Fernández-Moreno M, […]
Read MoreA peer reviewed paper on a study analyzing the capacity of APPA to modulate the inflammatory response induced by IL-1β in human articular chondrocytes and cartilage has been published in the Pharmaceuticals Journal. The paper was authored by Mercedes Fernández-Moreno, Tamara Hermida-Gómez, Nicholas Larkins, Alan Reynolds and Francisco Blanco. Pharmaceuticals 2024, 17(1), 118; https://doi.org/10.3390/ph17010118. Full text of the […]
Read MoreThe leading international journal in this field, Osteoarthritis & Cartilage, has published the paper “The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial”. Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Alan Reynolds, Nicholas Larkins, Peter Alexandersen, Helene Rovsing, Robert Moots […]
Read MoreNew data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggests that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on senescence – a process in which cells stop dividing as a natural consequence of ageing. Senescence plays a major role in the development of many […]
Read MoreOsteoarthritis affects one in seven adults in the US, with more than half of patients of working age. There are currently no effective and well tolerated oral therapies that provide long term relief for the symptoms of OA or reduce its progression. With APPA, AKL believes it has the only drug with a mechanism of action […]
Read More